Exclusive: What’s in Five Prime Therapeutics Inc After Today’s Big Decline?

Exclusive: What's in Five Prime Therapeutics Inc After Today's Big Decline?

The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) is a huge mover today! About 224,641 shares traded hands. Five Prime Therapeutics Inc (NASDAQ:FPRX) has risen 56.53% since March 9, 2016 and is uptrending. It has outperformed by 49.12% the S&P500.
The move comes after 9 months negative chart setup for the $1.34 billion company. It was reported on Oct, 12 by Barchart.com. We have $44.87 PT which if reached, will make NASDAQ:FPRX worth $120.60M less.

Analysts await Five Prime Therapeutics Inc (NASDAQ:FPRX) to report earnings on November, 2. They expect $-0.53 EPS, up 43.01% or $0.40 from last year’s $-0.93 per share. After $-0.49 actual EPS reported by Five Prime Therapeutics Inc for the previous quarter, Wall Street now forecasts 8.16% negative EPS growth.

Five Prime Therapeutics Inc (NASDAQ:FPRX) Ratings Coverage

Out of 5 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Five Prime Therapeutics has been the topic of 8 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by Wells Fargo on Friday, December 4. The company was initiated on Friday, July 31 by Citigroup. The firm earned “Sell” rating on Friday, August 21 by Zacks. On Monday, October 19 the stock rating was maintained by Oppenheimer with “Outperform”. Credit Suisse maintained Five Prime Therapeutics Inc (NASDAQ:FPRX) rating on Friday, March 11. Credit Suisse has “Outperform” rating and $52 price target. Credit Suisse initiated the stock with “Outperform” rating in Thursday, January 21 report. BMO Capital Markets initiated it with “Market Perform” rating and $50 target price in Tuesday, April 12 report. The rating was upgraded by Zacks to “Sell” on Tuesday, August 11.

According to Zacks Investment Research, “Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California.”

Insitutional Activity: The institutional sentiment increased to 2.29 in Q2 2016. Its up 1.04, from 1.25 in 2016Q1. The ratio improved, as 15 funds sold all Five Prime Therapeutics Inc shares owned while 34 reduced positions. 47 funds bought stakes while 65 increased positions. They now own 24.20 million shares or 3.63% more from 23.35 million shares in 2016Q1.
Pacad Inv holds 6,300 shares or 0.04% of its portfolio. Northern Trust Corporation has 0% invested in the company for 324,934 shares. Connor Clark And Lunn Ltd has 32,925 shares for 0.01% of their US portfolio. Parametric Portfolio Limited Com has invested 0% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX). Moreover, Eventide Asset Limited Liability has 2.75% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX) for 1.09M shares. Globeflex Lp holds 0.31% or 27,541 shares in its portfolio. Blackrock Advisors Llc has invested 0% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX). Meeder Asset Mgmt reported 6,480 shares or 0.03% of all its holdings. The Ohio-based Strs Ohio has invested 0% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Putnam holds 55,144 shares or 0.01% of its portfolio. The Maryland-based Proshare Advisors Lc has invested 0.01% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Deutsche Bank & Trust Ag last reported 138,805 shares in the company. State Board Of Administration Of Florida Retirement System last reported 27,374 shares in the company. Lord Abbett And reported 196,350 shares or 0.03% of all its holdings. Springbok Cap Mngmt Lc holds 0.01% or 2,500 shares in its portfolio.

Insider Transactions: Since April 14, 2016, the stock had 2 insider purchases, and 6 insider sales for $4.19 million net activity. Shares for $2.34M were sold by Williams Lewis T on Wednesday, April 20. RINGO WILLIAM R sold 500 shares worth $26,000. $286,607 worth of Five Prime Therapeutics Inc (NASDAQ:FPRX) shares were bought by BERGER FRANKLIN M. Belsky Marc also sold $1.71 million worth of Five Prime Therapeutics Inc (NASDAQ:FPRX) shares. 12,195 shares were sold by Jensen Peder, worth $603,653 on Wednesday, July 27.

Another recent and important Five Prime Therapeutics Inc (NASDAQ:FPRX) news was published by Streetinsider.com which published an article titled: “Five Prime Therapeutics (FPRX) Commences Cabiralizumab Combo Phase 1b in CSF1R” on October 04, 2016.

FPRX Company Profile

Five Prime Therapeutics, Inc. (Five Prime), incorporated on December 20, 2001, is a clinical-stage biotechnology firm focused on discovering and developing protein therapeutics. The Firm has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Firm seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company’s product candidates include FPA008, FPA144 and FP-1039/GSK3052230.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment